Actelion Share Price

Stocks

31/17/31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/17/22	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/17/18	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/17/20	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/17/18	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/17/05	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/17/31	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
23/17/23	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/20/06	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/17/30	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/17/16	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
16/17/16	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/18/29	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/18/29	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/18/22	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/17/30	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTELION	-.--%	+0.99%	-	-	0
ARGENX SE	+0.93%	+6.97%	+59.60%	+68.35%	5.73TCr
WUXI APPTEC CO., LTD.	-1.92%	+6.03%	+40.64%	+83.42%	5.5TCr
INSMED INCORPORATED	-0.46%	-1.29%	+2.86%	+428.78%	2.32TCr
BIONTECH SE	-2.97%	-2.35%	-22.53%	-16.40%	2.26TCr
WUXI BIOLOGICS (CAYMAN) INC.	-0.36%	+5.73%	+24.13%	-6.24%	2.05TCr
GENMAB A/S	-1.34%	+0.51%	+26.03%	-29.41%	1.76TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.44%	+5.67%	+38.77%	+504.71%	1.57TCr
PHARMAESSENTIA CORPORATION	-1.30%	-5.02%	+170.77%	+291.37%	1.45TCr
EXELIXIS, INC.	-0.50%	-0.98%	+21.43%	+180.07%	1.39TCr
Average	-0.94%	+1.28%	+40.19%	+167.18%	2.67TCr
Weighted average by Cap.	-0.87%	+2.10%	+39.70%	+133.49%